Piboserod

Piboserod
Clinical data
Trade names	Serlipet
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Clinical phase II;
Identifiers
	IUPAC name N-((1-Butyl-4-piperidyl)-methyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-a)indole-10-carboxamide;
CAS Number	152811-62-6 ;
PubChem CID	177336;
IUPHAR/BPS	225;
ChemSpider	154413 ;
UNII	4UQ3S81B25;
ChEMBL	ChEMBL356359 ;
CompTox Dashboard (EPA)	DTXSID60165129 ;
Chemical and physical data
Formula	C22H31N3O2
Molar mass	369.509 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1;
	InChI InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26) ; Key:KVCSJPATKXABRQ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Piboserod is a selective 5-HT₄ receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI)^[1] completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure.

Clinical data

Trade names	Serlipet
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Clinical phase II
Identifiers
IUPAC name N-((1-Butyl-4-piperidyl)-methyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-a)indole-10-carboxamide
CAS Number	152811-62-6^Y
PubChem CID	177336
IUPHAR/BPS	225
ChemSpider	154413^N
UNII	4UQ3S81B25
ChEMBL	ChEMBL356359^N
CompTox Dashboard (EPA)	DTXSID60165129
Chemical and physical data
Formula	C₂₂H₃₁N₃O₂
Molar mass	369.509 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
InChI InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)^N Key:KVCSJPATKXABRQ-UHFFFAOYSA-N^N
^NY (what is this?) (verify)